SHP2 inhibition may also reduce incidence of resistance to other Ras-pathway targeting therapeutics, SHP2 inhibition seen to ameliorate resistance to osimertinib, the EGFR inhibitor, in lung adenocarcinoma cell lines (Sealover et al., 2024). This evidence concerns the gene PTPN11 and lung adenocarcinoma.